Objective. To study the effects of nasal deformity on aerosol penetration past the nasal valve (NV) for varying particle sizes using sprays or nebulizers.
T opical drug administration into the nasal cavity has become a widely prescribed form of delivering medications such as intranasal steroids for the treatment of sinonasal inflammatory, allergic, and infectious disorders. Topical nasal medication targets affected sites with minimal systemic absorption, minimizing the risk of systemic side effects and the development of antibiotic resistance in nontargeted areas. 1 Intranasal medications are usually administered by nasal drops, aqueous spray pumps, and nebulizers. Spray pumps are most commonly used 2, 3 despite the fact that experimental studies have shown many spray devices deposit a significant amount of their drug in the anterior, less metabolically active regions of the nasal cavity. [3] [4] [5] [6] This anterior deposition is probably due to inertial impaction, since most spray pumps are designed to release a large proportion of aerosol particles greater than 20 µm, which exit the devices at a relatively rapid speed when actuated.
A number of studies have suggested that nasal nebulization is a more effective method of delivering topical medication beyond the nasal valve region than aqueous spray pumps. 2, 3, 5, 7 This enhanced penetration is attributed to the fact that nebulizers are designed to generate small, slow moving particles that traverse the nasal cavity at a resting breathing rate, thereby minimizing inertial impaction anterior to the nasal valve. 3, 5 In addition to the delivery device, a combination of other factors can also contribute to the efficacy of intranasal medications. These include drug formulation characteristics, site of deposition, underlying sinonasal medical condition, patient technique in the use of the delivery device, and nasal anatomy. 8, 9 Human nasal anatomy is particularly significant since it is characterized by variations across individuals that can be accentuated by disease. In particular, the presence of nasal anatomic deformities such as septal deviation may severely impede particle transport.
Recent advances in computational technology have made computer simulation a viable way to provide consistent objective measures of nasal airflow and function. Computational fluid dynamics (CFD) techniques can be used to simulate the flow of air, estimate drug delivery through 3-dimensional (3D) reconstructions of the nasal cavity. A number of validated CFD studies of nasal spray deposition have been conducted, 4, [10] [11] [12] [13] [14] [15] indicating that these methods can be used to make reliable predictions.
However, none of these studies investigated the effects of nasal deformity and particle size on nebulized aerosol deposition pattern in the nasal cavity. The objective of the present study, therefore, was to use CFD techniques to compare drug delivery penetration past the nasal valve of aqueous spray pumps and nebulizers in a patient with nasal airway obstruction due to septal deviation.
Materials and Methods

Nasal Model Construction
A 3D nasal airway model of a 30-year-old white female subject (weight, 86.4 kg; height, 164.6 cm) with a moderate to severe leftward septal deviation and a compensatory right inferior turbinate hypertrophy ( Figure 1A ) was created from computed tomography (CT) scans containing 142 slices, with an increment of 0.625 mm, and a pixel size of 0.313 mm. The subject provided informed consent as required, and the Institutional Review Board at Medical College of Wisconsin approved the study. The CT scan files were imported into the medical imaging software Mimics 13.1 (Materialise, Inc., Plymouth, Michigan), which was used to create a 3D reconstruction of the main nasal airways from which the paranasal sinuses were omitted. The 3D reconstruction was exported from Mimics in STL file format into the CAD and mesh generating software package ICEM-CFD 12.1 (ANSYS, Canonsburg, Pennsylvania). Planar nostril and outlet surfaces as well as regions for tracking particle deposition in the nasal cavity were constructed ( Figure 1B) . The nasal cavity was separated into the following regions:
• left and right anterior lateral wall • left and right anterior septum • left and right middle lateral wall • left and right middle septum • nasopharynx
The anterior regions ranged from the nostrils up to the nasal valve area; the middle regions covered the turbinates and adjacent nasal septum, and the nasopharynx was defined as posterior to the turbinates and septum.
Drug Delivery Methods
To simulate the administration of topical medication into each nostril, simulations were configured to mimic drug delivery characteristics of aqueous spray pumps and nebulizers. The spray device attributes and particle sizes considered in this study were within the range represented by typical features of nasal sprays that have been widely studied in the literature. 4, 6, 10, 16 Thus simulations were conducted using spray speeds of 1, 3, or 10 meters per second, emitted at a plume angle of 68°. Three different monodisperse sprays and a polydisperse spray were simulated. The monodisperse spray simulations used particle sizes of 10, 20, and 50 µm, respectively; and the polydisperse simulation used a particle size distribution described by a Rosin Rammler particle size distribution (RRPSD) 17 set to range in aerodynamic diameter from 10 to 110 µm, with a mean diameter of 66 µm and a spread distribution parameter of 2.89 µm. The spray characteristics and particle sizes defined by RRPSD resemble the Pfeiffer PF-80 spray pump presented in Cheng et al. 16 The location at which simulated sprays were released was defined in the nasal vestibule to be 0.5 cm into the nose from the nostril surface and was directed laterally or to the side, away from the septum and toward the outer portion of the eye as recommended by Benninger et al. 18 Simulated nebulization was set up to mimic drug delivery by standard nebulizer devices manufactured by Sinus Dynamics (General Home Pharmacy, Inc, Westlake Village, California), ViaNase (Kurve Technology, Inc, Lynnwood, Washington), or a respiratory tube connected to a nasal pillow mask (Puritan-Bennett, Pleasanton, California).
1 Nebulizers were simulated using 4 different monodisperse particle sizes, 1, 3.2, 6.42, or 10 µm. The 1-and 3.2-µm sizes were chosen, based on information available from advertising material from Sinus Dynamics, while 6.42-µm and 10-µm sizes have been discussed in the literature. 1, 3 The transport of aerosolized particles by spray pump or nebulizer was simulated with the head held upright in a neutral position at about 0 o to the vertical plane.
Numerical Simulation of Airflow and Particle Trajectories
In order to solve the equations that govern fluid flow, a computational mesh of the nasal airspaces was created in ICEM-CFD using approximately 4 million graded tetrahedral elements with a 3-layer, prism-element boundary at the airway walls. Steady-state, laminar inspiratory airflow was simulated using the CFD software package Fluent 12.1.4 (ANSYS, Inc., Canonsburg, Pennsylvania) under pressuredriven conditions. The boundary conditions specified in Fluent to determine the airflow field were defined as follows: (1) a no-slip "wall" condition at the airway walls, with the assumption that the walls were stationary with zero air velocity at the air-wall interface; (2) a "pressure-inlet" condition at the nostrils with gauge pressure set to zero; and (3) a "pressureoutlet" condition at the outlet with gauge pressure set to −25.4 pascals, which generated a target steady-state flow rate of 15.7 liters per minute. This flow rate was twice the minute volume (amount of air inhaled in 1 minute, defined as tidal volume × respiratory rate) that was estimated from body weight using gender-specific power law curves. 19 Particle trajectories were calculated using the Discrete Phase Model in Fluent, assuming unit density and that particles were spherical, until each aerosolized particle deposited or exited the nasal cavity at the nasopharynx. Those particles that exited through the outlet at the nasopharynx were categorized as "escaped." This study did not track the final destination of particles that escaped the nasal cavity. For particles that deposited in the nasal cavity, the region where each particle deposited was tracked. Penetration percentage past the nasal valve area was estimated as follows:
where MS, ML, and N represent number of particles deposited on the middle septum, middle lateral wall, and nasopharynx, respectively. T is total number of particles released from the delivery device. A modified form of "difference to sum ratio" was used to express posterior aerosol penetration between the number of particles that deposited on the middle lateral and septal walls. The equation for expressing this ratio (percentage) is given as MS, ML, and N are as defined above. A positive LSWDR value indicates higher aerosol deposition on the lateral wall than on the septum. Particles that exited the nasal passage via the nasopharynx were expressed as
Here E is the number of particles that exited the nasal cavity at the nasopharynx, and T is as defined above.
To simulate aqueous spray pumps, the "solid cone" injection type was specified in Fluent, which generated particle trajectories that emanated from the spray release position at randomly dispersed angles within the spray cone region. Nebulizers were simulated by specifying "surface" as injection type and choosing a cross-sectional area at the nostrils from which to release aerosolized particles. Analysis and visualization of results were conducted using Fluent and the postprocessing software package Fieldview 12 (Intelligent Light, Lyndhurst, Pennsylvania). Figure 2 shows a wide variation in posterior aerosol penetration in the nasal cavity for different characteristics of the drug delivery device. Spray pump particle penetration past the nasal valve was greatest at 10 µm, with more than 96% posterior penetration at spray speed of 1 or 3 meters per second. CFD simulation results showed a significantly higher lack of aerosol penetration on the affected (left) side, which was most dramatic for larger particle sizes (spray pump >20 µm, and nebulizer with 10 µm). This implies that the likelihood of inertial impaction is enhanced by nasal anatomic deformity.
Results
From Figure 2 , it can be seen that nebulized posterior aerosol penetration was less than 4% on both sides of the nose at 1 and 3.2 µm. Predicted penetration was highest at 10 µm, with 96% aerosol deposition recorded on the right side, and 40% deposition on the affected side. Simulated results in Figure 3 show that nebulizers increased the number of escaped particles from the nasal cavity; 97% of particles of size 1 µm exited via the nasopharynx. Similarly, more than 94% and 59% of particles of sizes 3.2 and 6.42 µm, respectively, were predicted to have escaped. In general, the presence of a septal deviation on the affected (left) side did not negatively impact the rate at which particles exited the nasal cavity.
Posterior septal wall deposition was considerably higher with aqueous spray pumps on both sides of the nasal cavity than nebulizers (Figure 4) . Topical medications released at 1-meterper-second spray speed showed considerably more septal wall deposition, >94%, than other spray speeds. In addition, septal deviation enhanced particle deposition onto the septum. Drugs sprayed at 3 or 10 meters per second produced greatest lateral wall deposition on the unaffected side for 10-and 20-µm particles. CFD simulations predicted more lateral wall deposition on both sides of the nasal cavity during nebulization of 1-and 3.2-µm particles (Figure 4) . The results suggested that nebulized aerosol particles were more likely to deposit on the lateral wall than sprayed particles. Furthermore, particle deposition on the lateral wall during nebulization was negatively impacted by the presence of a septal deflection.
Simulated nebulizers showed a widespread deposition pattern, with extensive surface area coverage ( Figure 5) . However, a large portion of these particles bypassed the nasal airway, with smaller particle sizes exiting the nose at a high rate (Figure 3) . Posterior aerosol deposition was predicted to be increased on the unaffected (right) side relative to the affected side (Figures 3, 5) . Also, the unaffected side appeared to have more deposition around the middle meatus when drug delivery was by an aqueous spray pump.
Discussion
Previous studies examining topical nasal drug administration by nebulizers in anatomically correct subjects have generally reported increased aerosolized particle deposition past the anterior nasal cavity compared with aqueous spray pumps. 2, 3, 5 Kundoor and Dalby 2 and Suman et al 3 suggested that nasal nebulizers covered greater surface area. CFD simulation results indicated that the assertion of better posterior particle deposition by nebulizers might be misleading, at least for an anatomically deformed subject. Whereas the results of this preliminary study appeared consistent with what has been reported in the literature about nebulizers creating considerably more particle penetration past the nasal valve area, it appears most of these particles are not retained in the nasal cavity; rather, they exited via the nasopharynx. In their 1998 article, Suman and colleagues reported that drug delivery by nasal nebulizers could enhance particle deposition in the pharynx and lungs compared with aqueous sprays, 5 and their 1999 article suggested that lung deposition is the result of particle size within the range of 2 to 10 µm. 3 The results presented in this study show that aqueous spray pumps generally achieve more aerosol posterior deposition in the nasal cavity relative to nebulizers. Septal deviation did not impact particle transport for 10-µm particles when administered by spray pumps. This trend was not observed for the larger particle sizes, for which noticeable penetration discrepancies were observed between both sides. In addition, aerosol penetration increased at slower spray speeds. Simulations predicted that posterior aerosol retention in the nasal cavity increased exponentially with larger particle sizes (from 1 µm to 10 µm) during nebulization, particularly on the unaffected side. Highest aerosol penetration occurred at the 10-µm particle size on both sides of the nose, with both simulated delivery devices.
CFD has several advantages over other methods to assess nasal deposition such as scintigraphy, endoscopic visualization with aerosolized dye, CT imaging with contrast medium, or quantification of radioactivity with surgical compresses. First, patients are not exposed to any radiation other than diagnostic CT scans. Second, quantitative, regional deposition patterns can be obtained to a much greater accuracy than is possible with other methods. Third, extensive studies of particle deposition effects of many spray and delivery device characteristics, as well as patient-use factors such as head position, nozzle insertion, and breathing behaviors, can be conducted far more quickly and cost effectively than is possible using in vivo methods, due to limitations on the number of subjects and trials in each subject that can be studied.
There are a number of potential clinical implications of this study. Simulations suggested that the correction of a septal deviation may greatly enhance drug delivery. The clinical scenario of a patient with an underlying mucosal inflammatory process-for example, rhinitis or sinusitis-coupled with an anatomic nasal deformity is a common one. Surgical correction of an underlying anatomic deformity may greatly increase the efficacy of medical management. On the other hand, a temporary presurgical management strategy for the treatment of such inflammation should involve topical medications capable of generating small aerosolized particles in the neighborhood of 10 µm if aqueous spray is to be prescribed. In addition, these results suggest that patients may be advised not to spray medication forcefully, as this seems to limit penetration of the drug. Similarly, if drugs are to be administered by nebulization, a system that generates particles with optimal mass median aerodynamic diameter greater than 6.42 µm may improve aerosol retention in the nose.
Although this study identified and quantified the potential effects of a moderate to severe septal deviation and particle size characteristics on topical intranasal medication, our airflow simulations were limited to laminar, steady-state conditionsmeaning that turbulence and the cyclic nature of airflow were not modeled. Furthermore, these results reflect the nasal anatomy of a single subject with some evidence of nasal cycling, for which this preliminary study did not account. In the future, a cohort of patients experiencing nasal airway obstruction with interindividual differences in nasal anatomy will be compared preoperatively and postoperatively.
